The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development
Open accessAbstract
Despite more than two decades of use, the optimal maintenance dose of tacrolimus for kidney transplant recipients is unknown. We hypothesized that HLA class II de novo donor-specific antibody (dn DSA) development correlates with tacrolimus trough levels and the recipient’s individualized alloimmune risk determined by HLA-DR/DQ epitope mismatch. A cohort of 596 renal transplant recipients with 50,011 serial tacrolimus trough levels had HLA-DR/DQ eplet mismatch determined using HLAMatchmaker software. We analyzed the frequency of tacrolimus trough levels below a series of thresholds <6 ng/ml and the mean tacrolimus levels before dn DSA development in the context of HLA-DR/DQ eplet mismatch. HLA-DR/DQ eplet mismatch was a significant multivariate predictor of dn DSA development. Recipients treated with a cyclosporin regimen had a 2.7-fold higher incidence of dn DSA development than recipients on a tacrolimus regimen. Recipients treated with tacrolimus who developed HLA-DR/DQ dn DSA had a higher proportion of tacrolimus trough levels <5 ng/ml, which continued to be significant after adjustment for HLA-DR/DQ eplet mismatch. Mean tacrolimus trough levels in the 6 months before dn DSA development were significantly lower than the levels >6 months before dn DSA development in the same patients. Recipients with a high-risk HLA eplet mismatch score were less likely to tolerate low tacrolimus levels without developing dn DSA. We conclude that HLA-DR/DQ eplet mismatch and tacrolimus trough levels are independent predictors of dn DSA development. Recipients with high HLA alloimmune risk should not target tacrolimus levels <5 ng/ml unless essential, and monitoring for dn DSA may be advisable in this setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, Š., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J. M., Frei, U., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067411 · Cited by 1,810
KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary
Kasiske, B. L., Zeier, M. G., Chapman, J. R., Craig, J. C., Ekberg, H., Garvey, C. A., Green, M. D., Jha, V., Josephson, M. A., Kiberd, B. A., et al. (2010) · Kidney International · doi:10.1038/ki.2009.377 · Cited by 1,735
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Eckardt, K.-U., Kasiske, B. L., & Zeier, M. G. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02834.x · Cited by 1,499
Haas, M., Sis, B., Racusen, L. C., Solez, K., Glotz, D., Colvin, R. B., Castro, M. C. R., David, D. S. R., David-Neto, E., Bagnasco, S. M., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12590 · Cited by 1,350
Self-citationWiebe, C., Gibson, I. W., Blydt-Hansen, T. D., Karpinski, M., Ho, J., Storsley, L. J., Goldberg, A., Birk, P. E., Rush, D. N., & Nickerson, P. W. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04013.x · Cited by 950
Self-citationThe KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Josephson, M. A. (2013) · Cited by 898
Identifying Specific Causes of Kidney Allograft Loss
El-Zoghby, Z. M., Stegall, M. D., Lager, D. J., Kremers, W. K., Amer, H., Gloor, J. M., & Cosio, F. G. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02519.x · Cited by 801
OPTN/SRTR 2015 Annual Data Report: Kidney
Hart, A., Smith, J. M., Skeans, M. A., Gustafson, S. K., Stewart, D. E., Cherikh, W. S., Wainright, J. L., Kucheryavaya, A., Woodbury, M., Snyder, J. J., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14124 · Cited by 445
Ekberg, H., Bernasconi, C., Tedesco-Silva, H., Vítko, S., Hugo, C., Demirbas, A., Reyes Acevedo, R., Grinyó, J., Frei, U., Vanrenterghem, Y., et al. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02726.x · Cited by 334
Neuberger, J. M., Bechstein, W. O., Kuypers, D. R. J., Burra, P., Citterio, F., De Geest, S., Duvoux, C., Jardine, A. G., Kamar, N., Krämer, B. K., et al. (2017) · Transplantation · doi:10.1097/tp.0000000000001651 · Cited by 315
Cited by
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Brunet, M., van Gelder, T., Åsberg, A., Haufroid, V., Hesselink, D. A., Langman, L., Lemaitre, F., Marquet, P., Seger, C., Shipkova, M., et al. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000640 · Cited by 707
Long-Term Survival after Kidney Transplantation
Hariharan, S., Israni, A. K., & Danovitch, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2014530 · Cited by 664
Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report
Tambur, A. R., Campbell, P., Claas, F. H., Feng, S., Gebel, H. M., Jackson, A. M., Mannon, R. B., Reed, E. F., Tinckam, K., Askar, M., et al. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14752 · Cited by 297
Self-citationImpact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation
Rao, N., Carcella, T., Patel, N., Bartlett, F., Posadas, M. A., Casey, M., Dubay, D. A., & Taber, D. J. (2023) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000494 · Cited by 5
Metadata
- Authors
- Wiebe, C., Rush, D. N., Nevins, T. E., Birk, P. E., Blydt-Hansen, T., Gibson, I. W., Goldberg, A., Ho, J., Karpinski, M., Pochinco, D., Sharma, A., Storsley, L., Matas, A. J., & Nickerson, P. W.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2017-07-20
- Volume
- 28
- Issue
- 11
- Pages
- 3353-3362
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- OpenAlex
- W2739465434
- Cited by
- 280
- References
- 14
- FWCI
- 22.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development. https://app.cochat.ai/papers/10.1681/asn.2017030287
- The paper
- Wiebe, C., Rush, D. N., Nevins, T. E., Birk, P. E., Blydt-Hansen, T., Gibson, I. W., Goldberg, A., Ho, J., Karpinski, M., Pochinco, D., Sharma, A., Storsley, L., Matas, A. J., & Nickerson, P. W. (2017). Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2017030287
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.